Skip to content

Live Cell Monitoring Could Accelerate Oncology Drug Discovery

By News Analysis India · · 1 min read

Dr. Shyam Agrawal, who leads the oncology department at Sir Ganga Ram Hospital, emphasized that live‑cell monitoring technology offers researchers a window into real‑time cellular responses to experimental drugs. This capability allows quick spotting of minute biochemical shifts, sharpening the selection of promising treatment pathways during early‑stage research.

He pointed out that integrating comprehensive genome sequencing with minimal residual disease tracking sharpens precision oncology, helping clinicians deliver more accurate, patient‑specific cancer therapies.

Parimita Mishra, the Indian‑born biotech innovator heading Precigenetics in San Francisco, described her platform as a way to gather continuous biochemical data from intact cells, removing the necessity for conventional staining, fixation, or cell disruption procedures. This uninterrupted observation reveals patterns previously hidden from view.

Mishra added that the technology's reach goes far beyond cancer, influencing fields such as immunology, neuroscience, rare disease diagnostics, and tissue regeneration. By forgoing reliance on isolated endpoint assays, scientists can monitor cellular dynamics over time, gaining richer insight into drug action.

The journey of cancer drug development is notoriously difficult, with many candidates faltering before clinical trials due to inadequate laboratory models that fail to replicate the full complexity of living cells.

Data from the International Agency for Research on Cancer shows that India saw about 1.4 million new cancer diagnoses in 2022, and domestic research councils warn that the national cancer load will keep climbing in the upcoming decade.